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Vasopressin promotes renal water reabsorption decreasing
excretion of free water to dilute plasma and lower serum
osmolality. We have good understanding of the causes,
mechanisms and consequences of this vasopressin-
dependent renal water movement. In comparison,
vasopressin actions on renal electrolytes including sodium
excretion and its consequences have been less well
understood. This is so for investigation and discussions of the
renal actions of vasopressin are framed primarily around
water metabolism rather than any direct effect on salt
handling. The fact that water moves in biological systems, to
include the mammalian kidney, only by osmosis passively
down its concentration gradient is implicit in such discussion
but often not overtly addressed. This can cause confusion.
Moreover, although vasopressin action on renal sodium
excretion via the V2 receptor is critical to water transport, it is
masked easily being situational—for instance, dependent on
hydration state. It is now clear that an increase in sodium
reabsorption along the distal nephron (CNT þ CD) mediated
by activation of the epithelial Naþ channel (ENaC) by
vasopressin makes an important contribution to
maintenance of the axial corticomedullary osmotic gradient
necessary for maximal water reabsorption. Thus, we need to
modify slightly our understanding of vasopressin and its
renal actions to include the idea that while vasopressin
decreases free water excretion to dilute plasma, it does this,
in part, by promoting sodium reabsorption and consequently
decreasing sodium excretion via ENaC activated along the
distal nephron.
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Vasopressin is thought to possess antinatriuretic actions
along with its better described antidiuretic actions.1–8 This is
supported by a preponderance of findings from cultured
renal cell lines, and renal tissue studied in isolation, including
perfused tubules and split-open collecting ducts, demonstrat-
ing that vasopressin increases luminal to serosal sodium
reabsorption by activating the epithelial Naþ channel
(ENaC).2,3,7,9–23 This effect should reduce sodium excretion
in vivo. However, investigation of water and electrolyte
handling in animals and humans show vasopressin to have
variable effects on net sodium excretion.4–6,8,24–33 New
understanding of the cellular mechanism and systemic
consequences of vasopressin action, in combination with
reconsideration of earlier findings, reveals why this is so.
VASOPRESSIN SIGNAL TRANSDUCTION
Vasopressin targets two receptor types, V1 and V2.34–37 Both
are seven transmembrane G-protein coupled receptors. The
former couples to phospholipase C via Gq/11 and the latter to
Gs, ultimately increasing cyclic adenosine monophosphate
(cAMP) by stimulating adenylyl cyclase. V1 receptors are
most abundant in vascular smooth muscle cells and their
stimulation favors contraction. V2 receptors are in epithelial
cells, such as principal cells of the distal nephron, and their
stimulation increases renal water reabsorption.34–37 Stimula-
tion of V1 receptors, although not directly involved in
control of tubular water and electrolyte transport, increases
sodium excretion because of the influences on blood
pressure, effective circulating volume, glomerular filtration
rate and circulation in the vasa recta system.24,34,38,39 As
illustrated in Figure 1, activation of V2 receptors in the distal
nephron by vasopressin stimulates free water reabsorption by
promoting cAMP-dependent trafficking of aquaporin 2 water
channels to the luminal membrane of principal cells allowing
back diffusion of water down its concentration gradient. In
addition, as a focus of the current review, vasopressin via V2
receptors also modulates discretionary sodium reabsorption
across principal cells mediated by ENaC. This facilitates free
water reabsorption by supporting the axial corticomedullary
hyperosmotic gradient. Vasopressin via V2 receptors also
activates urea transporters, such as UTA1, in the distal
nephron to facilitate urea reabsorption and urea recycling,
which allows maximization of sodium reabsorption in the
thick ascending limb via NKCC2 supporting the axial
hyperosmotic gradient drawing water from the distal
nephron (reviewed by Sands and Layton40 and Fenton41).
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HISTORICAL PERSPECTIVE
The first clues that vasopressin might decrease renal sodium
excretion came from early micropuncture studies and renal
tissue fluid sampling circa 1950–60.42,43 As reproduced in
Figure 2, these studies demonstrated that ‘y antidiuretic
hormone enhances the sequestration of sodium in the
interstitial fluids of the medulla and papilla’.42 Importantly,
vasopressin increased the absolute amount of sodium per
unit of dry solids showing that increases in medullary sodium
concentration were independent of effects on water. The
converse was also established where decreases in vasopressin
lowered the absolute amount of sodium in medullary
interstitial fluid. Such findings combined with our under-
standing of osmotic water movement demonstrate that the
effects of vasopressin on sodium transport are primary and
contribute to water movement. Also established by pioneer-
ing work in renal physiology is that the ability to concentrate
urine is dependent on systemic sodium levels with sodium
depletion, hyponatremia and removal of plasma sodium with
dialysis compromising this ability.44–48
SYSTEMIC CONSEQUENCES OF VASOPRESSIN ACTION
Elevated and lower than normal urinary sodium concentra-
tions and excretion have been reported for humans with
hyponatremia resulting from upregulated and uncontrolled
vasopressin secretion.24,25,49–51 This is so, as discussed below,
because the effects of vasopressin on renal sodium excretion
are situational and easily obscured. The renal consequences of
vasopressin on sodium excretion include both primary
causative actions as well as secondary responses. Moreover,
vasopressin controls excretion of free water by manipulating
both water permeability and the movement of solute, notably
urea and sodium.34–37 The latter makes control of systemic
water and sodium linked to some degree with one in some
instances capable of masking or impairing proper regulation
of the other. When considering vasopressin action on sodium
excretion, it is important to understand that it is only one
component of a larger multifactorial homeostatic control
system governing systemic sodium balance with most input
into this system responding to changes in plasma sodium
levels rather than water levels. Thus, vasopressin effects on
sodium excretion in the whole animal cannot be considered
in isolation and must be viewed in the context of other
signals also affecting systemic sodium balance. Similarly, a
change in renal sodium excretion in response to vasopressin
is just one component of a larger homeostatic control system
governing systemic water balance and must be considered in
the context of other input, such as the activity of the
renin–angiotensin II–aldosterone system (RAAS).
A recent study by Perucca et al.26 that precisely teased
apart contribution from specific V1 and V2 receptor agonism
and antagonism to renal water and sodium handling in rats
demonstrated that vasopressin via V2 receptors decreases
renal sodium excretion in addition to decreasing water
excretion. As recapitulated in Figure 3, specific V2 agonism
acutely decreased sodium excretion in a dose-dependent
manner, while promoting free water reabsorption and
lowering urea excretion. Antagonism of this receptor results
in the opposite response: increased sodium and water
excretion and urine dilution. Addition of exogenous
vasopressin capable of stimulating both V1 and V2 receptors
decreases sodium excretion and promotes free water
Figure 1 |Vasopressin signal transduction. AC, adenylyl cyclase;
AQP2, aquaporin 2; AVP, arginine vasopressin; cAMP, cyclic
adenosine monophosphate; ENaC, epithelial Naþ channel;
MR, mineralocorticoid receptor; Nedd4-2, neural precursor cell
expressed developmentally downregulated 4-2; Sgk, serum and
glucocorticoid-inducible kinase.
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Figure 2 |Vasopressin increases papillary sodium and urea
concentrations while concentrating urine. Figure regenerated
from data presented originally in Levitin et al.42 AVP, arginine
vasopressin.
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reabsorption at low doses and at higher doses increases
sodium excretion marginalizing free water reabsorption with
the latter as proven with specific agonists and antagonists
reflecting input from V1 receptors and compensation to
obligatory water retention. Thus, activation of V2 favors
antidiuresis associated with antinatriuresis, whereas, activa-
tion of V1 favors natriuresis. These observations in rat appear
to hold for humans, for vasopressin and preferential
activation of V2 receptors also reduces sodium excretion in
healthy human subjects and those having nephrogenic
diabetes insipidus as a result of aquaporin 2 mutation but
not those with mutation of the V2 receptor.4,6
As demonstrated many years ago in a seminal study from
Leaf et al.,24 ‘y the state of hydration determines the effect
of pitressin on electrolyte excretion.’ The salient finding in
this study performed in humans was that under rigid control
of electrolyte and water consumption, exposure to exogenous
vasopressin, presented as the posterior pituitary extract,
pitressin, only increased sodium excretion secondarily to
promoting water retention. This has been reconfirmed
recently with the natriuretic response to vasopressin, when
observed, brought about principally along the length of the
proximal tubule in compensation to volume expansion and
increases in blood pressure.52 Such compensation is capable
of obscuring vasopressin-dependent decreases in sodium
excretion with secondary increases in sodium excretion
temporally following antidiuresis, water retention and
development of hyponatremia. This establishes a chronolo-
gical cause and effect relation: antidiuresis in response to
vasopressin is almost immediate with secondary increases in
sodium excretion delayed by days.24 As expected then,
secondary increases in sodium excretion end upon correction
of volume changes by either promoting water diuresis
following cessation of vasopressin treatment or severely
restricting water intake.24,26 These findings and those above,
in accord with other observations that endogenous vaso-
pressin released by dehydration does not cause natriu-
resis,5,53–55 resolve most of the controversy surrounding the
apparent conflicting reports of vasopressin action on renal
sodium excretion. The presentation of vasopressin as either
antinatriuretic or natriuretic depends on hydration state and
specific agonism of either V1 or V2 receptors with
vasopressin in the presence of hypervolemia favoring
increases in sodium excretion and in the presence of
euvolemia and hypovolemia favoring decreases in sodium
excretion.5,6,24,26 As summarized in Figure 4, which was
originally presented in,26 a natriuretic response to vasopressin
mediated by V1 receptor stimulation and/or in compensation
to obligatory fluid retention can mask direct antinatriuretic
actions on renal epithelia mediated by V2 receptors. With
such a response, changes to volume predominate lessening
the maximal urine concentrating ability of vasopressin shown
as declining urine osmolality in the presence of increasing
sodium excretion. Decreased sodium excretion in response to
vasopressin reflects a primary antinatriuretic response via V2
receptors favoring water reabsorption not obscured by
responses to changes in volume. Thus, not unexpectedly, in
some instances, homeostatic control of sodium and volume
compete with homeostatic control of water and osmolality
obscuring direct actions of vasopressin on sodium excretion.
In consideration of the above and the fact that water
handling due to osmosis must be linked to some degree with
sodium handling, one might predict that the direct effects of
vasopressin and other salt retaining signals, such as
aldosterone, would be additive with respect to their action
on distal nephron sodium reabsorption, and sodium and
water excretion. This is exactly what was reported for the
actions of pitressin in the absence and presence of exogenous
adrenocorticotropic hormone; and what is documented by
more recent investigation of aldosterone and vasopressin
action on sodium and water excretion, and sodium flux and
ENaC activity in whole animal studies, isolated perfused
tubules and split-open collecting ducts.8–11,56
V2 RECEPTOR BLOCKADE
Another point of contention causing confusion are findings
that selective antagonism of V2 receptors acts primarily as an
aquaretic having no or only little effect on electrolyte
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Figure 3 |Vasopressin via V2 receptors (V2Rs) decreases
sodium excretion (excr.) while concentrating urine. Figure
originally presented in Perucca et al.26 and partially reproduced
here. Mean data presented as fold changes under experimental
(Exp) conditions as normalized to starting (basal) values in the
same rats. Paired t test vs basal; *Po0.05, **Po0.01, ***Po0.001.
BW, body weight.
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excretion.56–58 Restated, the aquaretic actions of V2 antagon-
ism are far larger than their natriuretic effects. This is at
variance to the actions of stronger diuretics. The reason for
this is that vasopressin influences water movement by
affecting both sodium transport and water permeability.
Moreover, vasopressin only transiently affects sodium excre-
tion. In the study by Perucca et al.,26 the diuretic but not
natriuretic actions of V2 antagonism persisted over a 24 h
period. Acute natriuretic actions of V2 antagonism, though,
are apparent at earlier time points but wan thereafter as
sodium is retained to compensate for marked water (volume)
loss. Notably, most studies reporting contrary findings about
the effect of vasopressin (or specific V2) antagonism on
electrolyte excretion focus on the 24 h or later time point.59–61
Indeed, careful inspection of these conflicting studies show in
agreement marked increases in sodium excretion at earlier
time points upon V2 receptor inhibition.59,61,62 This is
consistent with the concept that blocking vasopressin action
on renal epithelia during water retention leads to an acute
but transient natriuretic response contributing to margin-
alization of free water reabsorption. This makes sense if
compromise of a well-developed axial corticomedullary
hyperosmotic gradient favoring free water reabsorption
requires only transient increases in sodium excretion. As
first suggest in 1962 by Levitin et al.,42 ‘ythe total quantity
of sodium necessary to raise the content of sodium of the
medulla from that observed during water diuresis to that
present during hydropenia is very small.’ Following logically,
reversal of a state favoring water reabsorption to one favoring
water excretion requires only transient increase in sodium
excretion.
ENaC ACTIVITY SETS SODIUM REABSORPTION
IN THE DISTAL NEPHRON
Studies of the distal nephron in isolation provide direct proof
that vasopressin increases sodium reabsorption here. In
addition, the cellular mechanism and final effector associated
with increases in sodium reabsorption and thus, decreases in
excretion now have been unequivocally determined. Like
aquaporin 2, ENaC is in the apical membrane of principal
cells. Here, ENaC serves as the primary, if not only, gateway
for electrogenic sodium reabsorption. Consequently, ENaC
activity is limiting for discretionary Naþ reabsorption in this
tissue.63–67 ENaC is blocked by the Kþ -sparing diuretic
amiloride with inhibition increasing sodium excretion.63,68
As the limiting step in Naþ reabsorption and a target of the
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Figure 4 | Schematic representation of the dose-dependent effects of AVP on sodium excretion rate and dissociation of these
effects into V2 receptor (V2R)- and V1aR-mediated responses. Figure from Perucca et al.26 The abscissa represents increasing levels of
plasma AVP from left (undetectable) to right. A corresponds to the lowest values of AVP, which reduce urine flow rate but not sodium
excretion rate. V2R antinatriuretic and V1aR natriuretic effects are depicted as sigmoid curves with different thresholds (B for V2R and C for
V1 effects). (B0 and C0) Correspond to the maximum effects depending on each receptor type, respectively. M corresponds to the value of
plasma AVP for which the antinatriuretic and the natriuretic effects compensate each other. This value probably fluctuates according
to a number of factors influencing the intensity of the responses mediated by each of the two receptor types. Insert showing
dose-dependent effects of AVP on urine osmolality also from Perucca et al.26 Dashed line indicates AVP dosage that results in decreases in
sodium excretion that favor reabsorption of free water (left) from those resulting in increases in sodium excretion compromising urine
concentrating ability. AVP, arginine vasopressin; Exp, experimental.
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adrenal corticosteroid aldosterone, ENaC serves as a critical
end effector of RAAS governing plasma Naþ levels and thus,
blood volume and pressure via negative feedback regula-
tion.65–67 The importance of ENaC and its proper regulation
to renal Naþ handling is clear when considering the
inappropriate sodium retention and hypertensive phenotype
associated with ENaC gain of function, and the renal sodium
wasting associated with loss of function.66,67,69 Thus,
increases and decreases in ENaC activity are causative for
changes in renal sodium excretion.
VASOPRESSIN INCREASES ENaC ACTIVITY
Indication that ENaC is involved in a physiologically
important vasopressin response first came from a series of
detailed studies by the Schafer and Burg laboratories in
isolated perfused tubules.2,3,10–14,70 As recapitulated in
Figure 5, vasopressin increases the potential difference across
the isolated collecting duct consistent with increasing active
ion transport.2,3,10–14,70 The increase in potential difference
upon exposure to vasopressin is caused by a dose-dependent
change in net sodium flux (sodium reabsorption) from the
luminal fluid to serosal bath fluid with the lumen becoming
more hyperpolarized.3,10–14,70 Moreover, vasopressin-depen-
dent increases in sodium flux and transepithelial voltage
changes are often associated with decreases in transepithelial
resistance (and increases in conductance) consistent with
activation of apical sodium channels.2,11,70 The inhibitor of
ENaC, amiloride, abolishes this sodium flux, and changes in
voltage and resistance pointing to flux through this channel
as the limiting step in vasopressin-dependent sodium
reabsorption.10,11 Concomitant with increases in net lumen
to serosal sodium flux are increases in water permeability and
water reabsorption from the luminal to serosal fluid.12,13
Although the above studies strongly supported vasopres-
sin activation of ENaC in the mammalian collecting duct,
direct evidence for this was obtained only recently. We used
patch clamp electrophysiology to specifically test whether
vasopressin increases ENaC activity in the isolated, split-open
murine collecting duct. As represented in Figure 6, vaso-
pressin increases ENaC activity by increasing channel open
probability (Po) and the number (N) of channels in the apical
plasma membrane.9 ENaC in tubules isolated from water
restricted animals also had elevated activity in response to
increases in endogenous vasopressin.9 Inhibition of cAMP
signaling compromised increases in ENaC activity in
response to vasopressin and water restriction. Vasopressin
via cAMP signaling is known to promote trafficking and
insertion of ENaC into the apical membrane of principal
cells.18,71–74
Vasopressin, in addition, has a robust effect on amiloride-
sensitive short-circuit current across cultured epithelial cells,
and ENaC activity in immortalized renal epithelial cells.17–23
cAMP has similar actions on ENaC in cultured cells and
increases sodium flux and the Naþ conductance of the
luminal membrane in isolated tubules.11,18,19,70,75 Such
observations demonstrate that vasopressin uses V2 receptors
coupled to Gs and stimulation of adenylyl cyclase and
production of cAMP as a common signaling pathway to
increase both ENaC and aquaporin 2 activity. At a cellular
level, the previous increases sodium reabsorption to strengthen
osmotic draw of water and the latter increases water
permeability.
VASOPRESSIN AND ALDOSTERONE ACT IN A SYNERGISTIC
MANNER
As shown in Figure 7, ENaC is most active in tubules that
come from animals deprived of both water and Naþ or
treated with both aldosterone and vasopressin.9–11,13,14 This is
consistent with findings that vasopressin has its greatest effect
to decrease sodium excretion in hypovolemic states.5,26,50
ENaC, though, also is active during conditions, such as high
dietary sodium intake combined with water restriction, that
promote water but not necessarily sodium conservation
supporting the idea that vasopressin has a quantitatively
important action on ENaC during water reabsorption
uncoupled from the role played by the channel in sodium
balance. This action is to decrease sodium excretion to
facilitate water reabsorption. Consistent with this, mice with
tissue specific deletion of the mineralocorticoid receptor in
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Figure 5 |Vasopressin increases amiloride-sensitive luminal
to serosal sodium flux (Jlb; left) and transepithelial voltage
(Ve; right) in the isolated perfused rat collecting tubule.
Figures originally from Reif et al.,10 control (C), antidiuretic
hormone (ADH) and ADH þ amiloride (AMIL) indicated control
plus vasopressin in the absence and presence of AMIL.
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principal cells show increased water excretion when stressed
with low salt.76 Similarly, urinary concentrating defects are
known to result from adrenal insufficiency emphasizing the
importance of the additive effects vasopressin and aldoster-
one have on ENaC to decrease sodium excretion and support
water reabsorption.77
At a cellular level, convergence arises, in part, from
vasopressin via cAMP/protein kinase A and aldosterone via
serum and glucocorticoid-inducible kinase relieving negative
regulation of ENaC by phosphorylating and inhibiting the
negative regulator neural precursor cell expressed devel-
opmentally downregulated 4-2.78 Neural precursor cell
expressed developmentally downregulated 4-2 is an ubiquitin
ligase that promotes removal of ENaC from the plasma
membrane.
CONCLUSION
It is important to remember that, although vasopressin
actions on net sodium excretion by the kidney are situational
and easily obscured when placed in the context of whole
animal responses, nephron segments expressing the V2
receptor respond to vasopressin by increasing sodium
reabsorption in support of an antidiuretic response. Stated
another way, the causative primary actions of vasopressin on
ENaC and thus, distal nephron sodium transport always
supports antidiuresis by decreasing sodium excretion but this
may be obscured by secondary actions or the actions of other
hormones or factors influencing sodium balance rather than
water homeostasis.
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